Enaltus has recently acquired the properties of Mitchell-Vance Laboratories. Mitchell Vance is a portfolio firm of the HealthEdge Investment Fund LP based out of Tampa Florida.
Mitchell-Vance is best known as ScarAway and produces over the counter topical silicone scar medications and treatments sold in over 20,000 retail stores. It is a FDA regulated medical device that uses silicone technology that helps improve the size and appearance of scars, especially keloidal and hypertrophic scars.
Enatlus operates out of Suwannee, Geogia and is focused on the development, marketing and selling skincare products to physicians and retailers.
According to Jeff Thompson, Enaltus CEO and HealthEdge Partner, "Enaltus has become a leading provider in the professional and retail scar management category across the U.S. and a significant player in the specialty skincare market through strong organic growth of its core brands, licensing of new brands, and strategic acquisitions, including Belli Skincare, a leader in skincare solutions for pre and post natal women and infants, MedAltus, a provider of complete e-commerce skin store solutions for physicians, and now ScarAway."
President of Mitchell-Vance Laboratories Jessica Rowen added, "We are excited about the acquisition of ScarAway by Enaltus and believe the combined portfolio of brands will gain additional distribution and benefit from similar, but different, experiences in the scar management category. The combination of the ScarAway and Kelo-cote brands will enhance our capability to provide customers with best in class professional-grade scar treatment solutions."
Join the Conversation